Incyte Corporation is jettisoning a suite of immunotherapy programs to focus on more high-value assets in its pipeline, particularly as its flagship drug Jakafi (ruxolitinib) gets closer to losing market exclusivity. The pipeline shake-up includes a number of immuno-oncology drug candidates.
The Wilmington, DE-based drug maker reported its second quarter earnings on 30 July, posting $1bn in revenue that represented 9% growth year over year. Revenue from Jakafi – used to...
Key Takeaways
-
Incyte’s second quarter earnings included better-than-expected sales for Jakafi and Opzelura.
-
The company reshuffled its pipeline, discontinuing several immuno-oncology assets targeting PD-L1, LAG-3...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?